Back to NVSEFView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMAPending
Zelnorm
Zelnorm is indicated for the repeated symptomatic short-term treatment of women with Irritable Bowel Syndrome (IBS) whose predominant bowel habit is constipation, associated with abdominal pain/discomfort or bloating (see section 4.2).
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
FingolimodPhase 3
Multiple Sclerosis
dovitinibPhase 3
Solid Tumors
MF59-eH1N1_fPhase 3
Influenza
Glycopyrronium bromidePhase 3
Chronic Obstructive Pulmonary Disease
Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccinePhase 3
Swine-Origin Influenza A H1N1 Virus
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts